Treatment strategies for calcium pyrophosphate deposition disease

Abstract

Calcium pyrophosphate deposition disease (CPPD) is a cause of inflammatory arthropathy that increases in prevalence with increasing age, presents in acute and chronic forms, and is characterized by the finding of positively birefringent crystals on polarized microscopy of synovial fluid. This review finds that although strides are being made in CPPD diagnosis and classification, CPPD remains a poorly understood, unrecognized, and debilitating disease. As a consequence, treatment options usually lack supportive evidence and there has been little progress in novel drug development for the condition. This article aims to discuss the updated evidence on treatment options for CPPD and identifies promising future areas for improvement.

Keywords

Pseudogout / calcium pyrophosphate deposition disease / treatment / therapy / management / chondrocalcinosis / arthritis

References

[1] Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016; 374: 2575-84.

[2] Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003; 62: 513-8.

[3] Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022; 8: e002383.

[4] Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis Rheumatol. 2023; 75: 1703-13.

[5] Cai K, Fuller A, Zhang Y, Hensey O, Grossberg D, Christensen R, et al. Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. Semin Arthritis Rheum. 2021; 51: 946-50.

[6] Zhang W, Doherty M, Pascual E, Barskova V, Guerne P, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Ann Rheum Dis. 2011; 70: 571-5.

[7] Zhang W, Doherty M, Bardin T, Barskova V, Guerne P, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Ann Rheum Dis. 2011; 70: 563-70.

[8] Guo SY, Lee CA, Wise BL. Chondrocalcinosis and Osteoarthritis: A Literature Review. Eur J Rheumatol. 2023;[Epub ahead of print].

[9] Pascart T, Robinet P, Ottaviani S, Leroy R, Segaud N, Pacaud A, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol. 2023; 5: e523-31.

[10] Laosuksri P, Phrintrakul N, Gumtorntip W, Na-Nan K, Wongthanee A, Kasitanon N, et al. Non-loading versus Loading low-dose colchicine in acute crystal-associated arthritis: A double-blinded randomized controlled study. Int J Rheum Dis. 2023; 26: 2478-88.

[11] Damart J, Filippou G, Andrès M, Cipolletta E, Sirotti S, Carboni D, et al. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis. Rheumatology (Oxford). 2024; 63: 446-55.

[12] Dumusc A, Maldonado BP, Benaim C, Zufferey P, Aubry-Rozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study. Joint Bone Spine. 2021; 88: 105088.

[13] Lian A, Shandilya A, Riordan J. A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease. Clin Rheumatol. 2023; 42: 1833-7.

[14] Dang RR, Noonan V, Chigurupati R, Henry A. Treatment of tophaceous pseudogout in the temporomandibular joint with resection and alloplastic reconstruction: a single-staged approach. Oral Maxillofac Surg. 2022; 26: 505-9.

[15] O’Duffy JD. Pseudogout syndrome in hospital patients. JAMA. 1973; 226: 42-4.

[16] Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986; 13: 804-5.

[17] Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996; 63: 248-54.

[18] Roane DW, Harris MD, Carpenter MT, Finger DR, Jarek MJ, Alloway JA, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997; 24: 1168-70.

[19] Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014; 81: 98-100.

[20] Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994; 21: 1325-7.

[21] Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988; 31: 803-5.

[22] Finckh A, Carthy GMM, Madigan A, Linthoudt DV, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014; 16: 458.

[23] Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012; 18: 234-6.

[24] Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997; 23: 327-31.

[25] Latourte A, Ea H, Frazier A, Blanchard A, Lioté F, Marotte H, et al. Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. Ann Rheum Dis. 2020; 79: 1126-8.

[26] Uson J, Rodriguez-García SC, Castellanos-Moreira R, O’Neill TW, Doherty M, Boesen M, et al. EULAR recommendations for intra-articular therapies. Ann Rheum Dis. 2021; 80: 1299-305.

[27] Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-41.

[28] Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010; 48: 407-14.

[29] Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: A systematic review. Semin Arthritis Rheum. 2021; 51: 84-94.

[30] Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009; 68: 1119-24.

[31] Daoussis D, Antonopoulos I, Andonopoulos AP. ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action. Semin Arthritis Rheum. 2014; 43: 648-53.

[32] Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994; 21: 696-9.

[33] Cipolletta E, Matteo AD, Scanu A, Isidori M, Battista JD, Punzi L, et al. Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review. Clin Exp Rheumatol. 2020; 38: 1001-7.

[34] Altomare A, Corrado A, Maruotti N, Cici D, Cantatore FP. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease. Mol Biol Rep. 2021; 48: 4789-96.

[35] Moret CS, Iordache E, D’Ambrosi R, Hirschmann MT. Chondrocalcinosis does not affect functional outcome and prosthesis survival in patients after total or unicompartmental knee arthroplasty: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2022; 30: 1039-49.

[36] Abou-Foul AK, Saeed NR. Treatment of calcium pyrophosphate deposition in the temporomandibular joint with resection and simultaneous reconstruction using a custom joint prosthesis. Oral Maxillofac Surg. 2020; 24: 235-8.

[37] Kathju S, Cohen R, Lasko L, Aynechi M, Dattilo DJ. Pseudogout of the temporomandibular joint: immediate reconstruction with total joint arthroplasty. Head Neck. 2010; 32: 406-10.

[38] Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. Risk factors for pseudogout in the general population. Rheumatology (Oxford). 2012; 51: 2070-4.

[39] Yashiro T, Hara H, Ito K, Tanaka R, Fukuuchi A, Yamashita T, et al. Pseudogout associated with primary hyperparathyroidism: management in the immediate postoperative period for prevention of acute pseudogout attack. Endocrinol Jpn. 1988; 35: 617-24.

[40] Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983; 42: 106-7.

[41] Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, et al. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. J Immunother Cancer. 2019; 7: 126.

[42] Young-Min SA, Herbert L, Dick M, Fordham J. Weekly alendronate-induced acute pseudogout. Rheumatology (Oxford). 2005; 44: 131-2.

[43] Wendling D, Tisserand G, Griffond V, Saccomani C, Toussirot E. Acute pseudogout after pamidronate infusion. Clin Rheumatol. 2008; 27: 1205-6.

[44] Watanabe H, Yamada S, Anayama S, Sato E, Maekawa S, Sugiyama H, et al. Pseudogout attack induced during etidronate disodium therapy. Mod Rheumatol. 2006; 16: 117-9.

[45] Kim ST, Tayar J, Fu S, Ke D, Norry E, Sun A, et al. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. J Immunother Cancer. 2021; 9: e002716.

[46] Soriano F, Campana V, Moya M, Gavotto A, Simes J, Soriano M, et al. Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results. Photomed Laser Surg. 2006; 24: 140-50.

[47] Stack J, McCarthy G. Calcium pyrophosphate deposition (CPPD) disease-Treatment options. Best Pract Res Clin Rheumatol. 2021; 35: 101720.

[48] Abhishek A, Doherty M. Pathophysiology of articular chondrocalcinosis-role of ANKH. Nat Rev Rheumatol. 2011; 7: 96-104.

[49] Chang C, Lee K, Chan T, Chung C, Liang Y. Histone Deacetylase Inhibitors Downregulate Calcium Pyrophosphate Crystal Formation in Human Articular Chondrocytes. Int J Mol Sci. 2022; 23: 2604.

[50] Iqbal SM, Qadir S, Aslam HM, Qadir MA. Updated Treatment for Calcium Pyrophosphate Deposition Disease: An Insight. Cureus. 2019; 11: e3840.

[51] Danino O, Svetitsky S, Kenigsberg S, Levin A, Journo S, Gold A, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology (Oxford). 2018; 57: 1472-80.